The world is currently in the grip of a diabetes epidemic. A recent major study by Majid Ezzati and colleagues from Imperial College London and Harvard University found that the number of adults with type 2 diabetes increased from an estimated 153 million in 1980 to 347 million in 2008. The number could be 370 million today.
Every region of the world is affected, although the epidemic is growing most rapidly in Oceania and least rapidly in East Asia. Globally, the type 2 diabetes epidemic has been growing in lockstep with rising obesity levels.
This is not surprising — an increase in body fat and a decrease in physical activity are the direct causes of type 2 (as opposed to type 1) diabetes.
In fact, much of the adverse effects of obesity and physical inactivity on physical health occur through diabetes.
These health effects are serious. Diabetes is already the major cause of kidney failure, blindness and lower-limb amputation in many countries, and a major cause of heart attacks and strokes.
Despite this, monitoring of diabetes remains relatively undeveloped throughout the world, even in high-income countries.
According to the Centers for Disease Control and Prevention, public health surveillance is “the ongoing systematic collection, analysis, interpretation and dissemination of health data for the purpose of preventing and controlling disease” — in short, information for action.
There is nothing in this definition that restricts surveillance to communicable diseases, yet in practice, this has generally been the case. The reasons are not hard to find. Communicable disease outbreaks occur over days and weeks (or at the most, months); the danger is “clear and present” and prevention and control generally requires intervention by the state — the quarantine of victims, tracing and immunization of contacts, or elimination of environmental sources of the infectious agent.
Chronic diseases like diabetes are very different. The epidemic happens silently over years or decades; the danger is either not recognized or not considered avoidable; and action is often seen as the responsibility of the individual (lifestyle modification) or healthcare system (pharmaceutical prescription), rather than the state.
Yet effective chronic disease surveillance can save lives. If disease trends are monitored, along with patients’ responses to treatment and the population’s exposure to risk factors, the success or failure of policies designed to prevent or control chronic diseases can be evaluated, resource allocation can be rationally prioritized and the public can be kept fully informed of the risks that they face.
Recognizing this, in December 2005, the New York City Board of Health mandated the laboratory reporting of test results for glycosylated haemoglobin (HbA1c) — a biomarker for diabetes and a key indicator of blood glucose control — thereby creating the world’s first population-based diabetes registry. Mandatory laboratory reporting of HbA1c results (along with basic demographic data) for a defined population (New York City residents) allowed New York’s Department of Health to monitor trends in diabetes prevalence, assess testing coverage and examine healthcare use and glycemic control of residents living with diabetes.
Beyond these population-based surveillance functions, the registry was able to support patient care by ensuring that individual healthcare providers and patients were made aware of elevated or rising HbA1c levels. Both the patient-support function and the surveillance function required the use of a unique patient identifier so that letters could be mailed to patients and tests from the same patient could be linked over time.
In 2009, Thomas Frieden and colleagues from the New York City Board of Health reviewed the registry’s first four years of operation and concluded that it was performing well. Getting all laboratories to report regularly and completely, however, proved challenging and not all healthcare providers and patients proved willing to participate.
The board’s initiative has been widely praised as exemplifying the application of classical communicable disease surveillance-and-control tools to a chronic disease. Other commentators, however, have criticized the registry, saying it was potentially compromising patient confidentiality and privacy, and even disrupting the relationship between patients and their doctors.
While these criticisms may or may not be justified, it is probably true to say that the New York City diabetes registry, though highly innovative, is at best an interim solution.
Rather than relying on laboratory reporting of a single biomarker, an ideal chronic-disease surveillance system would extract all necessary data directly from the patient record.
Any diagnosis of diabetes, or subsequent monitoring of disease progression, requires a medical consultation and hence an entry into the patient record — and so into the practice’s patient-management information system. Logically, the surveillance system should operate by extracting the entire subset of data required for surveillance purposes from each healthcare provider’s patient management information system (“front-end capture”).
This data would then be securely transferred (electronically) to a suitable data warehouse. After appropriate cleaning (checking for missing data, correcting coding errors), and anonymizing, the data would be available for access and querying. Given appropriate statistical analysis and careful interpretation, useful reports could be generated for surveillance purposes and, if desired, for patient care support as well (using encrypted unique patient identifiers to preserve confidentiality of personal information).
In view of the rising burden of diabetes and other chronic diseases throughout the world, urgent attention must be devoted to strengthening surveillance systems for noncommunicable diseases at all levels — from local practices to global institutions.
Martin Tobias is a public health physician in Wellington, New Zealand.
Copyright: Project Syndicate
Could Asia be on the verge of a new wave of nuclear proliferation? A look back at the early history of the North Atlantic Treaty Organization (NATO), which recently celebrated its 75th anniversary, illuminates some reasons for concern in the Indo-Pacific today. US Secretary of Defense Lloyd Austin recently described NATO as “the most powerful and successful alliance in history,” but the organization’s early years were not without challenges. At its inception, the signing of the North Atlantic Treaty marked a sea change in American strategic thinking. The United States had been intent on withdrawing from Europe in the years following
My wife and I spent the week in the interior of Taiwan where Shuyuan spent her childhood. In that town there is a street that functions as an open farmer’s market. Walk along that street, as Shuyuan did yesterday, and it is next to impossible to come home empty-handed. Some mangoes that looked vaguely like others we had seen around here ended up on our table. Shuyuan told how she had bought them from a little old farmer woman from the countryside who said the mangoes were from a very old tree she had on her property. The big surprise
Ursula K. le Guin in The Ones Who Walked Away from Omelas proposed a thought experiment of a utopian city whose existence depended on one child held captive in a dungeon. When taken to extremes, Le Guin suggests, utilitarian logic violates some of our deepest moral intuitions. Even the greatest social goods — peace, harmony and prosperity — are not worth the sacrifice of an innocent person. Former president Chen Shui-bian (陳水扁), since leaving office, has lived an odyssey that has brought him to lows like Le Guin’s dungeon. From late 2008 to 2015 he was imprisoned, much of this
The issue of China’s overcapacity has drawn greater global attention recently, with US Secretary of the Treasury Janet Yellen urging Beijing to address its excess production in key industries during her visit to China last week. Meanwhile in Brussels, European Commission President Ursula von der Leyen last week said that Europe must have a tough talk with China on its perceived overcapacity and unfair trade practices. The remarks by Yellen and Von der Leyen come as China’s economy is undergoing a painful transition. Beijing is trying to steer the world’s second-largest economy out of a COVID-19 slump, the property crisis and